PHARMA MAR, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.96 EUR | +0.49% |
|
+10.37% | -29.50% |
| Apr. 23 | Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 29 | Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024 |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 966.8 | 1,792 | 1,232 | 800.7 | 510.8 | - | - |
| Enterprise Value (EV) 1 | 828 | 1,625 | 1,039 | 672 | 327.2 | 233.3 | 510.8 |
| P/E ratio | 6.98 x | 19.3 x | 25.1 x | 737 x | 11.3 x | 5.85 x | 3.92 x |
| Yield | 1.15% | 0.66% | - | - | 1.7% | 2.27% | - |
| Capitalization / Revenue | 3.58 x | 7.8 x | 6.28 x | 5.06 x | 2.61 x | 2.14 x | 2.26 x |
| EV / Revenue | 3.07 x | 7.07 x | 5.29 x | 4.25 x | 1.67 x | 0.98 x | 2.26 x |
| EV / EBITDA | 5.07 x | 16.6 x | 20.8 x | 322 x | 3.78 x | 1.78 x | 14.2 x |
| EV / FCF | 3 x | 90.9 x | 35.3 x | -22.9 x | 4.9 x | 2.34 x | - |
| FCF Yield | 33.3% | 1.1% | 2.83% | -4.38% | 20.4% | 42.7% | - |
| Price to Book | - | 10 x | 5.56 x | 4.03 x | 2.18 x | 1.79 x | - |
| Nbr of stocks (in thousands) | 18,496 | 18,113 | 18,011 | 18,108 | 17,640 | - | - |
| Reference price 2 | 52.27 | 98.95 | 68.42 | 44.22 | 28.96 | 28.96 | 28.96 |
| Announcement Date | 2/26/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Maart | 2020 | 2021 | 2022 | 2023 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 270 | 229.8 | 196.3 | 158.2 | 195.9 | 238.5 | 225.8 |
| EBITDA 1 | 163.2 | 98.03 | 49.97 | 2.084 | 86.67 | 131.3 | 36 |
| EBIT 1 | 155.9 | 92.45 | 44.07 | -3.827 | 63.62 | 102.1 | 99.8 |
| Operating Margin | 57.77% | 40.22% | 22.45% | -2.42% | 32.48% | 42.81% | 44.2% |
| Earnings before Tax (EBT) 1 | 145.6 | 95.13 | 43.79 | -3.623 | 35.85 | 76.8 | 101.4 |
| Net income 1 | 137.3 | 92.86 | 49.36 | 1.137 | 56.88 | 91.72 | 109.4 |
| Net margin | 50.85% | 40.4% | 25.14% | 0.72% | 29.03% | 38.46% | 48.43% |
| EPS 2 | 7.490 | 5.130 | 2.730 | 0.0600 | 2.572 | 4.952 | 7.380 |
| Free Cash Flow 1 | 275.9 | 17.87 | 29.47 | -29.4 | 66.8 | 99.75 | - |
| FCF margin | 102.21% | 7.78% | 15.01% | -18.59% | 34.1% | 41.83% | - |
| FCF Conversion (EBITDA) | 169.13% | 18.23% | 58.97% | - | 77.08% | 75.95% | - |
| FCF Conversion (Net income) | 201.03% | 19.25% | 59.71% | - | 117.45% | 108.75% | - |
| Dividend per Share 2 | 0.6000 | 0.6500 | - | - | 0.4925 | 0.6567 | - |
| Announcement Date | 2/26/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 98.69 | 45.25 | 85.89 | 34.94 | 30.19 | 65.13 | 18.71 | 54.94 | 33.98 | 46.21 | 80.19 | 37.45 | 40.51 | 33.33 | 44.6 | 38 | 36.3 |
| EBITDA 1 | 40.57 | 12.49 | 44.82 | 20.6 | 11.31 | 31.94 | 12.56 | 5.436 | -1.258 | 5.418 | 4.16 | 1.309 | -3.385 | -3.3 | - | - | - |
| EBIT 1 | 37.95 | - | 43.36 | 19.01 | 9.829 | 28.84 | 11.86 | 3.372 | -2.572 | 4.047 | 1.475 | -0.184 | -5.118 | -3.467 | 0.3 | -2 | -8.6 |
| Operating Margin | 38.45% | - | 50.48% | 54.42% | 32.55% | 44.28% | 63.38% | 6.14% | -7.57% | 8.76% | 1.84% | -0.49% | -12.63% | -10.4% | 0.67% | -5.26% | -23.69% |
| Earnings before Tax (EBT) 1 | - | - | - | - | 11.99 | 32.61 | 14 | -2.821 | -3.217 | 4.497 | - | 1.57 | -6.473 | -1.1 | 0.3 | -2 | -8.4 |
| Net income 1 | 43.2 | 11.5 | 38.16 | 22 | 12.95 | 34.92 | 8.477 | 5.984 | 1.411 | 5.024 | 6.435 | 1.521 | -6.819 | -3.233 | 0.4 | -2.3 | -9.5 |
| Net margin | 43.78% | 25.41% | 44.43% | 62.97% | 42.88% | 53.62% | 45.32% | 10.89% | 4.15% | 10.87% | 8.02% | 4.06% | -16.83% | -9.7% | 0.9% | -6.05% | -26.17% |
| EPS 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.0700 | 0.0200 | -0.1100 | -0.4500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 7/29/21 | 10/28/21 | 2/28/22 | 4/28/22 | 7/27/22 | 7/27/22 | 10/27/22 | 2/28/23 | 4/26/23 | 7/27/23 | 7/27/23 | 10/26/23 | 2/28/24 | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 139 | 167 | 193 | 129 | 184 | 278 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 276 | 17.9 | 29.5 | -29.4 | 66.8 | 99.8 | - |
| ROE (net income / shareholders' equity) | 241% | 66.2% | 24.6% | 0.55% | 28.9% | 31.6% | - |
| ROA (Net income/ Total Assets) | 60.3% | 26.6% | 13% | - | 15.5% | 23.4% | - |
| Assets 1 | 227.5 | 349.3 | 380.8 | - | 366.9 | 392 | - |
| Book Value Per Share 2 | - | 9.850 | 12.30 | 11.00 | 13.30 | 16.20 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 3 | 7.8 | 8.85 | 16 | 9.4 | 10.5 | 16 |
| Capex / Sales | 1.11% | 3.4% | 4.51% | 10.09% | 4.8% | 4.4% | 7.09% |
| Announcement Date | 2/26/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
28.96
EUR
Average target price
49.2
EUR
Spread / Average Target
+69.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.50% | 545M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- PHM Stock
- Financials Pharma Mar, S.A.
